Authors
M Tschöp, TR Castaneda, HG Joost, C Thöne-Reineke, S Ortmann, S Klaus, MM Hagan, PC Chandler, KD Oswald, SC Benoit, RJ Seeley, KP Kinzig, TH Moran, AG Beck-Sickinger, N Koglin, RJ Rodgers, JE Blundell, Y Ishii, AH Beattie, P Holch, DB Allison, K Raun, K Madsen, BS Wulff, CE Stidsen, M Birringer, OJ Kreuzer, M Schindler, K Arndt, K Rudolf, M Mark, XY Deng, DC Withcomb, HOUR Halem, J Taylor, J Dong, R Datta, M Culler, S Craney, D Flora, D Smiley, ML Heiman
Publication date
2004/7/8
Journal
Nature
Volume
430
Issue
6996
Pages
1-3
Publisher
Nature Publishing Group UK
Description
Arising from: R. L. Batterham et al. Nature418, 650–654 (2002); Batterham et al. reply
Batterham et al. report that the gut peptide hormone PYY3–36 decreases food intake and body-weight gain in rodents, a discovery that has been heralded as potentially offering a new therapy for obesity. However, we have been unable to replicate their results. Although the reasons for this discrepancy remain undetermined, an effective anti-obesity drug ultimately must produce its effects across a range of situations. The fact that the findings of Batterham et al. cannot easily be replicated calls into question the potential value of an anti-obesity approach that is based on administration of PYY3–36.
Total citations
Scholar articles
M Tschöp, TR Castaneda, HG Joost, C Thöne-Reineke… - Nature, 2004
M Tschop, TR Castaneda, HG Joost, C Thone-Reineke… - Nature, 2004
M Tschöp, TR Castañeda, HG Joost, C Thöne-Reineke… - Nature, 2004
M Tschöp, TR Castañeda, HG Joost, C Thöne-Reineke… - 2004